Cytosorbents Statistics
Total Valuation
Cytosorbents has a market cap or net worth of $44.63 million. The enterprise value is $51.76 million.
| Market Cap | 44.63M |
| Enterprise Value | 51.76M |
Important Dates
The next estimated earnings date is Tuesday, July 30, 2024, after market close.
| Earnings Date | Jul 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytosorbents has 54.31 million shares outstanding. The number of shares has increased by 24.24% in one year.
| Shares Outstanding | 54.31M |
| Shares Change (YoY) | +24.24% |
| Shares Change (QoQ) | +16.56% |
| Owned by Insiders (%) | 3.20% |
| Owned by Institutions (%) | 37.06% |
| Float | 45.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.22 |
| Forward PS | 1.06 |
| PB Ratio | 2.36 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.49, with a Debt / Equity ratio of 0.91.
| Current Ratio | 1.49 |
| Quick Ratio | 1.26 |
| Debt / Equity | 0.91 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -278.69 |
Financial Efficiency
Return on equity (ROE) is -129.90% and return on invested capital (ROIC) is -77.95%.
| Return on Equity (ROE) | -129.90% |
| Return on Assets (ROA) | -55.00% |
| Return on Capital (ROIC) | -77.95% |
| Revenue Per Employee | $197,238 |
| Profits Per Employee | -$148,061 |
| Employee Count | 186 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 4.82 |
Taxes
| Income Tax | -813,739 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.72% in the last 52 weeks. The beta is 0.62, so Cytosorbents's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | -76.72% |
| 50-Day Moving Average | 0.85 |
| 200-Day Moving Average | 1.15 |
| Relative Strength Index (RSI) | 50.17 |
| Average Volume (20 Days) | 107,437 |
Short Selling Information
The latest short interest is 1.47 million, so 2.71% of the outstanding shares have been sold short.
| Short Interest | 1.47M |
| Short Previous Month | 1.52M |
| Short % of Shares Out | 2.71% |
| Short % of Float | 3.21% |
| Short Ratio (days to cover) | 18.86 |
Income Statement
In the last 12 months, Cytosorbents had revenue of $36.69 million and -$27.54 million in losses. Loss per share was -$0.59.
| Revenue | 36.69M |
| Gross Profit | 23.51M |
| Operating Income | -28.18M |
| Pretax Income | -28.35M |
| Net Income | -27.54M |
| EBITDA | -26.10M |
| EBIT | -28.25M |
| Loss Per Share | -$0.59 |
Balance Sheet
The company has $10.09 million in cash and $17.22 million in debt, giving a net cash position of -$7.13 million or -$0.13 per share.
| Cash & Cash Equivalents | 10.09M |
| Total Debt | 17.22M |
| Net Cash | -7.13M |
| Net Cash Per Share | -$0.13 |
| Equity (Book Value) | 18.93M |
| Book Value Per Share | 0.35 |
| Working Capital | 6.57M |
Cash Flow
In the last 12 months, operating cash flow was -$23.38 million and capital expenditures -$73,637, giving a free cash flow of -$23.45 million.
| Operating Cash Flow | -23.38M |
| Capital Expenditures | -73,637 |
| Free Cash Flow | -23.45M |
| FCF Per Share | -$0.43 |
Margins
Gross margin is 64.08%, with operating and profit margins of -76.80% and -75.07%.
| Gross Margin | 64.08% |
| Operating Margin | -76.80% |
| Pretax Margin | -77.29% |
| Profit Margin | -75.07% |
| EBITDA Margin | -71.13% |
| EBIT Margin | -77.01% |
| FCF Margin | -63.92% |
Dividends & Yields
Cytosorbents does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.24% |
| Shareholder Yield | -24.24% |
| Earnings Yield | -61.71% |
| FCF Yield | -52.55% |
Analyst Forecast
The average price target for Cytosorbents is $2.67, which is 224.90% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.67 |
| Price Target Difference | 224.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 11.24% |
| EPS Growth Forecast (5Y) | -30.08% |
Stock Splits
The last stock split was on December 5, 2014. It was a reverse split with a ratio of 1:25.
| Last Split Date | Dec 5, 2014 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
Cytosorbents has an Altman Z-Score of -8.67 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.67 |
| Piotroski F-Score | 4 |